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We report 4 cases of surgical resection of metachronous lymph node (LN) metastases from hepatocel-
lular carcinoma (HCC) following hepatectomy.  Clinicopathological features and results of LN dissec-
tion were investigated in the 4 patients.  One patient was found to have a single metastasis in the 
mediastinal LNs,  another had multiple metastases in the mediastinal and abdominal LNs,  and the 
other 2 had single metastases in the abdominal LN.  The locations of the abdominal LN metastases 
were behind the pancreas head in 2 patients and around the abdominal aorta in 1 patient.  They all 
underwent surgical resection of metastatic LNs and had no postoperative complications.  The 3 
patients whose LN metastases were solitary have been alive for more than 2 years after LN resection,  
and one of them is free from recurrence.  The patient with multiple LN metastases died 13 months 
after LN resection due to carcinomatosis.  With the expectation of long-term survival,  a single 
metachronous LN metastasis from HCC after hepatectomy should be resected in patients without 
uncontrollable intrahepatic or extrahepatic tumors.
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epatocellular carcinoma (HCC) is the most fre-
quent primary malignant tumor of the liver,  but 
the incidence of extrahepatic metastasis in HCC is 
lower than that in other hepatic cancers [1].  Hemato-
genous metastasis from HCC is well known to occur,  
with the most frequent site being the lung,  followed by 
the adrenal gland and skeleton [2,  3].  Autopsy stud-
ies have clariﬁed that the frequency of lymph node 
(LN) metastasis from HCC was 23.5-43.9ｵ [3-6].  
However,  LN metastasis after treatments has been 
described as uncommon (11.6ｵ),  accounting for only 
1.0ｵ of hepatectomy cases [4].  Although there have 
been many reports on the patterns and treatment of 
intrahepatic recurrence of HCC,  the modality of 
treatment for LN metastasis of HCC has not been 
fully discussed.  We herein report the clinical features 
of 4 patients who developed LN recurrence of HCC 
after hepatectomy,  and discuss the eﬀects of resection 
of the metastatic LNs.
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Case Report
　 Between January 2000 and January 2011,  554 
patients with HCC underwent hepatectomy in our 
department.  Four patients having isolated LN metas-
tasis without intrahepatic and other extrahepatic 
recurrence were selected for surgical removal of LN.  
Further resection of a metastatic LN was performed 
for one patient with the reappearance of a solitary LN 
metastasis following the initial resection of a meta-
static LN (Case 3).  There was no postoperative mor-
tality.  The clinicopathological features and prognosis 
of all 4 patients after LN resection are shown in 
Table 1.
　 Case 1. A 58-year-old woman had undergone 
percutaneous ethanol injection therapy (PEIT) and 
radiofrequency ablation therapy (RFA) for HCC in the 
right lobe for 4 years at another hospital.  Subse-
quently,  we performed right hemihepatectomy for HCC 
recurrence.  Two years later,  a single intra-abdominal 
tumor adjoining the posterior surface of the pancreas 
head was detected by follow-up ultrasonography.  
Dynamic computed tomography (CT) showed a swollen 
solitary mass 45mm in diameter with early enhance-
ment (Fig.  1A).  She was diagnosed with LN metasta-
sis of HCC by ﬁne needle biopsy under endoscopic 
ultrasonography.  Because there were no other distant 
metastases,  pancreaticoduodenectomy (PD) was per-
formed for resection of the LN metastasis (Fig.  1B).  
Histopathological examination of the resected mass 
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Fig. 1　 A, Dynamic computed tomography ﬁndings of case 1.  A solitary enlarged lymph node metastasis at the posterior pancreati-
coduodenal site can be seen,  having marked enhancement during the arterial phase (arrow); B,  Gross appearance of the resected lymph 
node.  The cut surface of this tumor revealed a yellow-brownish tumor,  45×25mm in diameter,  with a capsule.
Table 1　 Clinicopathological ﬁndings of primary tumors and outcomes of surgical resection of lymph node metastasis
Case Primary tumor LN recurrence
No.
Maximal
size
(cm)
Number Diﬀerentiation
Underlying
liver
pathology
Hepatectomy
Interval
from
hepatectomy
(month)
Location Number
Surgical
treatment
Survival
after LN
resection
(month)
Recurrence
after LN
resection
1 1.2 Multiple Undiﬀerentiated Normal Right
hemihepatectomy
24 Peripancreatic Single PD Alive (27) -
2 1.1 Multiple Modrately Hepatitis C Right
trisegmentectomy
19 Paraaortic
Mediastinal
Multiple
LN
dissection
Dead (13) LN
3 5.2 Single Modrately Hepatitis B Right
hemihepatectomy
21 Mediastinal Single＊ LN
dissection
Alive
(41＊＊) Bone
4 2.3 Single Well Normal Left
hemihepatectomy
31 Peripancreatic Single PD Alive (25) Liver
LN lymph node,  PD pancreaticoduodenectomy; ＊The ﬁrst and second lymph node metastasis; ＊＊After the ﬁrst lymph node dissection.
revealed metastatic HCC.  The patientʼs postoperative 
course was uneventful.  She is doing well without 
recurrence,  27 months after LN resection.
　 Case 2. A 72-year-old woman with hepatitis C 
infection presented with HCC in the right anterior 
superior segment (S8) in 1996 and underwent PEIT 
and RFA several times at another hospital,  but suf-
fered from HCC recurrence in the right lobe with 
hepatic infarction.  In March 2007,  she underwent 
right trisegmentectomy of the liver for HCC recur-
rence at our hospital.  Nineteen months later,  medi-
astinal and abdominal paraaortic lymphadenopathies,  
18mm and 36mm in diameter respectively,  were found 
by CT (Fig.  2A,  B).  Because there were no other 
distant metastases,  thoracolaparotomy was performed 
to dissect these lymph nodes.  Histopathological 
examination of the dissected LNs revealed metastasis 
of HCC.  Six months later,  aortic LN metastases 
were detected again.  She died of carcinomatosis 13 
months after the second operation.
　 Case 3. A 59-year-old man with hepatitis B 
infection presented with HCC in the right superior 
segment (S8,  S7) and underwent right hepatic lobec-
tomy in November 2005.  Twenty-one months later,  
lymphadenopathy in the mediastinum above the dia-
phragm was found by enhanced CT (Fig.  3A).  
Because there were no other distant metastases,  
thoracolaparotomy was performed to dissect this LN 
after transcatheter arterial embolization (TAE).  
Histopathological examination of the dissected LN 
revealed metastasis of HCC.  Eighteen months after 
the second operation,  LN recurrence adjacent to the 
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Fig. 2　 Dynamic computed tomography ﬁndings of case 2.  A,  An enlarged mediastinal lymph node above the left diaphragm (arrow) 
demonstrated moderate enhancement during the arterial phase; B,  A paraaortic lymph node (arrow) with marginal fat deposition was also 
found to be enlarged,  having mild enhancement during the arterial phase.
A B
Fig. 3　 Dynamic computed tomography (CT) ﬁndings of case 3.  A,  CT revealed a swollen mediastinal lymph node 35mm in diameter 
along the esophagus (arrow).  After TAE,  it had Lipiodol accumulation partially with little contrast material enhancement; B,  A mediastinal 
lymph node adjacent to the right atrium (arrow) enhanced mildly during the arterial phase.
right atrium in the mediastinum was detected by CT 
(Fig.  3B),  and repeated LN dissection was per-
formed as a third operation.  Three months after the 
third operation,  bone metastasis was detected.  The 
patient remains alive 41 months after the second 
operation.
　 Case 4. A 79-year-old man underwent left 
hemihepatectomy of the liver,  with a diagnosis of HCC 
in the medial segment (S4) in June 2006.  Thirty-one 
months after the hepatectomy,  a solitary metastatic 
tumor 40mm in diameter was detected in the pancre-
aticoduodenal LN by follow-up CT (Fig.  4A),  and he 
was diagnosed with LN metastasis of HCC.  Because 
there were no other distant metastases,  PD was per-
formed to resect the mass (Fig.  4B).  He had no 
postoperative complications.  The histopathology of the 
mass showed a metastatic LN from HCC.  Seventeen 
months after PD,  intrahepatic recurrence was 
detected and controlled by PEIT.  He is alive at 25 
months after the second surgery.
Discussion
　 LN metastasis from HCC is not rare,  and autopsy 
studies have clariﬁed that the frequency of LN metas-
tasis from HCC is 23.5-43.9ｵ [3-6].  Nonetheless,  
surgeons rarely ﬁnd LN metastasis during operations 
for HCC,  unlike for other cancers.  The prevalence of 
LN metastasis in patients who have undergone hepa-
tectomy for HCC was reported to be only 1.0ｵ [4].  
The cause of the discrepancy is associated with the 
following.  Most synchronous LN metastases usually 
occur in patients with advanced and poorly diﬀerenti-
ated HCC [6],  and most such patients do not receive 
surgical treatments.  Moreover,  we do not routinely 
perform LN dissection during surgery for HCC,  
because of the risk of lymphatic leakage and coagu-
lopathy caused by poor liver function and because of 
the low incidence of LN metastasis from HCC in the 
operable-stage disease [1,  7].
　 The hepatic lymphatic system has been well eluci-
dated [8].  Much of the lymph ﬂow towards the 
hepatic hilum runs into the intra-abdominal lymphatic 
system through the hepatoduodenal ligament;  
however,  some of the lymph ﬂow communicates with 
the diaphragmatic and intrathoracic lymphatic system 
through bilateral triangular ligaments.  It is very 
important that some HCC exhibits so-called skip 
metastasis,  which means there are no LN metastases 
in the proximal hepatoduodenal ligament but rather at 
distant sites [1,  9].  The prevalence of LN metastasis 
has been reported to be higher in patients without 
cirrhosis than with cirrhosis [6,  8].  Since the pro-
gression of cirrhosis leads to lymphatic obstruction,  
advanced cirrhosis may reduce the rate of LN 
metastasis; however cirrhosis leads to the formation 
of collateral routes for lymphatic drainage and these 
may produce skip metastasis [6].  Although no patient 
in this series had cirrhosis,  3 patients had skip metas-
tasis of paraaortic or retropancreatic LN; therefore,  
attention should be given to the possibility of skip LN 
metastasis in HCC patients.
　 LN metastasis of HCC is associated with a poorer 
prognosis,  and a standard treatment modality has not 
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Fig. 4　 A,  Dynamic computed tomography ﬁndings of case 4.  Swelling of the retropancreatic lymph node can be seen (arrow) with little 
enhancement; B,  Gross appearance of the resected mass.  The cut surface revealed a yellow-brownish tumor,  40×25mm in diameter,  
with a capsule.
been established.  Retrospective studies regarding 
radiotherapy to target LN recurrence of HCC agreed 
that LN metastasis from HCC was sensitive to radia-
tion therapy [10-12],  but Park et al.  [10] demon-
strated that radiotherapy for metastatic LN from HCC 
could have survival beneﬁt only to patients without 
other distant metastases or uncontrollable primary 
HCC and that the median survival time under the 
condition was 15 months.
　 Clinical researches employing surgical treatments 
for LN metastasis from HCC have been reported as 
small retrospective series [1,  5,  7,  9,  13,  14].  
Kobayashi et al.  [7] reported that selective lymph-
adenectomy,  in which only lymph nodes suspected of 
metastasis by preoperative radiologic imaging diagno-
sis were resected,  could improve the prognosis of 
selected patients who developed single LN metastasis 
without uncontrollable intrahepatic tumor or other 
extrahepatic metastases,  and that the median survival 
time was 29 months after surgery,  a period almost 
twice as long as the survival time after radiotherapy 
demonstrated by Park et al.  Other surgical series for 
synchronous and metachronous LN metastasis also 
recommended selective use of LN dissection for soli-
tary LN metastasis cases because the presence of 
multiple metastatic LNs implied the systemic nature 
of the disease,  and the alteration of lymphatic ﬂows by 
regional lymphadenectomy could lead to postoperative 
refractory ascites in cirrhotic patients.  [5,  9,  13,  
14].  As for the site of LN recurrence,  a good prog-
nosis was mainly achieved in patients with locore-
gional LN metastases in the hepatoduodenal ligament 
and/or on the posterior surface of the pancreatic 
head [1,  5,  9,  13],  but Hashimoto et al.  reported 2 
patients surviving for more than 2 years after resec-
tion of paraaortic LN metastasis [13].
　 In our case series,  which focused on surgical 
treatments of metachronous LN metastases in the 
absence of intrahepatic or extrahepatic lesions,  the 
patient with multiple distant LN metastases at the 
mediastinal and paraaortic sites died of carcinomato-
sis about a year after surgery while the others with a 
single LN metastasis survived for more than 2 years.  
Concerning the performed surgeries,  2 patients who 
developed a solitary retropancreatic LN metastasis 
with normal liver function underwent pancreaticoduo-
denectomy uneventfully to complete regional LNs 
dissection.  Consequently,  one of them survived 27 
months after surgery without recurrence; however,  
the case was considered to be rare and limited among 
the population suﬀering from HCC,  which usually 
originates from injured livers.
　 The eﬃcacy of Sorafenib,  a newer molecular tar-
geting agent,  has been recently veriﬁed for prolonging 
survival in patients with advanced HCC [15,  16].  
The American Association for the Study of Liver 
Disease guidelines on the management of HCC recom-
mend the use of Sorafenib for advanced-stage HCC 
with lymph node metastasis [16].  However,  the sur-
vival beneﬁts have not yet been demonstrated in a 
subgroup analysis of patients with extrahepatic metas-
tasis.
　 We concluded that long-term survival could be 
expected after surgical resection of metachronous LN 
metastasis of HCC following hepatectomy,  especially 
in patients developing a solitary metastatic LN with-
out concurrent uncontrolled intrahepatic or extrahe-
patic tumors.
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